OUR MISSION
Our mission is to help end human suffering, using innovative research and proprietary therapies, to advance humanity into a cancer-free future.
OUR VISION
To provide a therapy with the highest probability of positive response, while eliminating the dangers of conventional treatment, with compassionate.
SUCCESS
In April 2010, Dr. Matsumura and his colleagues at the ALIN Foundation announced an historic achievement: all cancer patients treated with the SEF Chemo® in 2006 not only went into remission, but remained cancer-free without the toxic side effects normally associated with chemotherapy.
The results on patients undergoing SEF Chemo® are nothing short of stunning. One oncologist, who regularly refers patients to us, remarked that he knows of no other place in the world where achievements such as ours are being accomplished.
Results are still early, but we are getting response on virtually every patient we treat, as compared to the 20-30% response rates of conventional chemotherapy on the types of cancers we are treating. If we begin treatment while the volume of cancer cells in a patient is still limited (as opposed to advanced late stage IV), we are achieving clinical remissions consistently. By clinical remission we mean that when we use imaging studies with x-rays, MRIs, or ultrasound we cannot find any trace of cancer.
Almost every patient we treat is responding to therapy.
3 Clinics Worldwide
We are proud to offer this revolutionary treatment to patients in 3 countries. Dr. Matsumura has personally trained every clinic to ensure the proper delivery of treatment. To find out more about where you can receive treatment, please use the Contact Form on the Inquiry Page.
PATIENT TESTIMONIALS
Listen to stories from some of our patients about their experience at the Berkeley Institute, in their own words.
JOHN
John was a patient with early-stage IV bladder cancer that came to the Berkeley Institute in October 2015. Before coming to us, he was told by his doctors that, even with the best conventional therapy had to offer, he would not live past 1-2 years.
“It has been five years since the tumors shrank and died from my SEF Chemo treatment. I’ve had yearly CT scans and 3-month urine cytology and FiSH tests, and my urologist said I must be very lucky, because with conventional chemotherapy, bladder cancer usually reoccurs within 6 months. My urologist is very optimistic that Dr. Matsumura may have achieved a cure.”
ESTHER
Esther came to the Berkeley Institute with stage I breast cancer. She is a registered nurse and saw patients undergo conventional cancer treatments.
“While deciding whether to do conventional chemotherapy, I learned about Dr. Matsumura’s SEF Chemo treatment. He and his staff met with me and answered all the questions I had. I opted to do his 8-week SEF Chemotherapy and received all the emotional support to help me deal with my diagnosis and treatment. I know I made the right decision.”
Esther completed the 8-week SEF Chemotherapy with no side effects and has been in remission since June of 2016.
JOSE
Jose, and his wife Alba, came to the Berkeley Institute after they had struggled through 8 years and millions of dollars in conventional cancer treatments for his prostate cancer that had spread to the liver. His liver had become six-times larger than normal, he had no appetite, and was near death.
“After only a few treatments of SEF Chemo, my liver shrunk by half. When I first came for a consultation at the Berkeley Institute, I had no appetite and was no longer eating. After a few weeks of treatment, I was going out to eat at restaurants with my wife. She won’t stop telling everyone my appetite was back!”
Have A Question?
We understand the burden placed on those who are dealing with a recent diagnosis, as well as the burden placed on their friends and families. To help better serve you and expedite communication, please use the form on the Contact Page. If you do not hear from us within 72 hours, please call:
(510) 250 – 5990.
Dr. Matsumura is a proud member of the following professional medical associations:
